Home › Hepatitis C › NCT05368974

The Treatment in Pregnancy for Hepatitis C ("TiP-HepC") Registry

An Observational Study of Mother-Infant Outcomes Following Antenatal Exposure to Direct-Acting Antivirals: the Treatment in Pregnancy for Hepatitis C ("TiP-HepC") Registry

Who can join

All ages · All sexes · Healthy volunteers welcome

Inclusion Criteria:

-Documented pregnancy with: Estimated date of conception by documentation of either 1) date of last menstrual period or 2) ultrasound evaluation Actual date of delivery

* Documented chronic HCV infection prior to or during pregnancy (positive test for HCV RNA or HCV core antigen)
* Documented DAA exposure occurring within 30 days of the estimated date of conception and before the pregnancy outcome (ie, fetal demise, spontaneous abortion, live delivery, etc). Eligible DAA drugs are listed in Appendix 1.

Exclusion Criteria:

\- DAA exposures that include ribavirin or interferon will be excluded given their established harm during pregnancy.

About the study

Clinical interventions to reduce the risk of vertical transmission of hepatitis C virus (HCV) infection from mother to infant are highly limited. Direct-acting antiviral (DAA) medications have demonstrated excellent safety and efficacy in non-pregnant individuals, but there is a lack of data regarding the safety of these medications in pregnant women and the effectiveness of these medications in reducing mother-to-child transmission. Therefore, although HCV screening during pregnancy is now recommended in many countries, there is no approved treatment for HCV during pregnancy. An observational study is here proposed to assess outcomes of mother-infant pairs exposed to DAAs during pregnancy within a global clinical case registry. Data regarding the exposures and outcomes of mother-infant pairs exposed to DAAs during pregnancy will be solicited and collected from clinical providers, healthcare facilities, HCV treatment programs, and other clinical practices worldwide. Data will be shared and maintained within a secure database, and cumulative data will be analyzed at pre-determined six-month intervals. The primary outcome will be the number and proportion of mother-infant pairs with adverse pregnancy or birth outcomes. The results of this study will inform HCV treatment decisions by clinical providers and programs worldwide.

What is being tested

• Direct Acting Antivirals (drug)

Sponsor: The Task Force for Global Health · Participants: 100 · Started: Feb 11, 2022

Contact the study team

• Neil Gupta, MD · Phone: 4043014134
• Lindsey Hiebert · Phone: 4043014134

Official record on ClinicalTrials.gov — NCT05368974

Locations in the U.S.

Conditions

• Hepatitis C

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.